[go: up one dir, main page]

MX2017009289A - Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. - Google Patents

Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.

Info

Publication number
MX2017009289A
MX2017009289A MX2017009289A MX2017009289A MX2017009289A MX 2017009289 A MX2017009289 A MX 2017009289A MX 2017009289 A MX2017009289 A MX 2017009289A MX 2017009289 A MX2017009289 A MX 2017009289A MX 2017009289 A MX2017009289 A MX 2017009289A
Authority
MX
Mexico
Prior art keywords
methods
high purity
pharmaceutical formulations
prepare
same
Prior art date
Application number
MX2017009289A
Other languages
English (en)
Other versions
MX391152B (es
Inventor
Motheram Rajeshwar
Rafai Far Adel
Ding Min
Dutta Panna
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55537309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2017009289A publication Critical patent/MX2017009289A/es
Publication of MX391152B publication Critical patent/MX391152B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
    • B65D81/2069—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas in a special atmosphere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a cangrelor de alta pureza, a formulaciones farmacéuticas que comprenden cangrelor de alta pureza como ingrediente activo, a métodos para preparar tales compuestos y formulaciones, y a métodos para utilizar las formulaciones farmacéuticas en la inhibición de la activación y agregación plaquetarias.
MX2017009289A 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. MX391152B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562103136P 2015-01-14 2015-01-14
PCT/US2015/039975 WO2016114818A1 (en) 2015-01-14 2015-07-10 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same

Publications (2)

Publication Number Publication Date
MX2017009289A true MX2017009289A (es) 2017-10-11
MX391152B MX391152B (es) 2025-03-21

Family

ID=55537309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009289A MX391152B (es) 2015-01-14 2015-07-10 Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.

Country Status (13)

Country Link
US (4) US9295687B1 (es)
EP (1) EP3244900A4 (es)
KR (1) KR102440847B1 (es)
CN (2) CN107206014A (es)
BR (1) BR112017014996A2 (es)
CA (1) CA2971868C (es)
CL (1) CL2017001840A1 (es)
CO (1) CO2017006958A2 (es)
MA (1) MA41326A (es)
MX (1) MX391152B (es)
PE (2) PE20171246A1 (es)
RU (1) RU2733409C2 (es)
WO (1) WO2016114818A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20200445T1 (hr) * 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
BR112013020377B1 (pt) * 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
EP3244900A4 (en) * 2015-01-14 2018-05-30 Chiesi Farmaceutici S.p.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
KR102768341B1 (ko) 2017-06-23 2025-02-18 키에시 파르마슈티시 엣스. 피. 에이. 체폐동맥 션트 혈전증의 예방 방법
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法
CN109781920B (zh) * 2017-11-15 2023-07-11 石药集团中奇制药技术（石家庄）有限公司 一种坎格雷洛有关物质的hplc检测方法
CN109912674A (zh) 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法
US20220040100A1 (en) * 2020-06-25 2022-02-10 RK Pharma Solutions LLC Stable Acyclovir Sodium Parenteral Formulation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2108425T3 (es) 1993-02-10 1997-12-16 Astra Pharma Prod Analogos de atp sustituidos con n-alquilo-2.
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
GB9813646D0 (en) * 1998-06-24 1998-08-26 Ciba Geigy Ag Organic compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
JP4272991B2 (ja) 2001-09-21 2009-06-03 大日本住友製薬株式会社 凍結乾燥製剤
KR100970528B1 (ko) 2002-02-22 2010-07-16 쉐링 코포레이션 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8680052B1 (en) * 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120184504A1 (en) * 2009-10-02 2012-07-19 Strony John T "The Use of a PAR-1 Antagonist in Combination with a P2Y12 ADP Receptor Antagonist for Inhibition of Thrombosis"
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
HRP20200445T1 (hr) * 2009-11-11 2020-06-12 Chiesi Farmaceutici S.P.A. Metode liječenja ili prevencije tromboze u stentu
BR112013020377B1 (pt) * 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
WO2013103567A2 (en) * 2012-01-04 2013-07-11 The Medicines Company Methods of blocking platelet activation during extracorporeal circulation using cangrelor
CN103860459A (zh) * 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
EP3244900A4 (en) * 2015-01-14 2018-05-30 Chiesi Farmaceutici S.p.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same

Also Published As

Publication number Publication date
RU2017127531A (ru) 2019-02-14
MA41326A (fr) 2021-04-28
CL2017001840A1 (es) 2017-12-29
WO2016114818A1 (en) 2016-07-21
RU2017127531A3 (es) 2019-02-14
CO2017006958A2 (es) 2017-11-30
CA2971868C (en) 2023-04-04
KR20170103848A (ko) 2017-09-13
US9439921B2 (en) 2016-09-13
RU2733409C2 (ru) 2020-10-01
CA2971868A1 (en) 2016-07-21
CN107206014A (zh) 2017-09-26
MX391152B (es) 2025-03-21
CN115990138A (zh) 2023-04-21
US20160199400A1 (en) 2016-07-14
PE20221170A1 (es) 2022-07-25
US9295687B1 (en) 2016-03-29
US20170304345A1 (en) 2017-10-26
PE20171246A1 (es) 2017-08-24
US9700575B2 (en) 2017-07-11
US10039780B2 (en) 2018-08-07
BR112017014996A2 (pt) 2018-03-20
EP3244900A4 (en) 2018-05-30
EP3244900A1 (en) 2017-11-22
KR102440847B1 (ko) 2022-09-06
US20160296549A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
ECSP21072161A (es) Composiciones de liberación retardada de linaclotida
IL254353A0 (en) Vaporizer for vaporizing an active ingredient
CL2018001710A1 (es) Derivados de pirazol activos como pesticida.
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO2017002472A2 (es) Formulación de acetato de abiraterona
BR112016018654A2 (pt) Composições de silicato estabilizadas e seu uso como composições antiperspirantes
IN2015DN03984A (es)
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112016006171A2 (pt) formulações de espuma e dispositivo para sua entrega
CO2017007316A2 (es) Formulación farmacéutica
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX390480B (es) Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
CO2018004665A2 (es) Compuestos oxadiazoespíricos
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
CO2019000083A2 (es) Composiciones farmacéuticas
GT201400115A (es) Combinación farmacéutica antineurítica y composición
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
GT201600190A (es) Compuestos químicos